A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis

Drug Safety

Volumn 18, Issue 1, 1998, Pages 43-56

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ANTIEMETIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; COST OF ILLNESS; HUMANS; RISK ASSESSMENT; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0031976099     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818010-00004     Document Type: Review

References (50)

1. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol 1992; 3 Suppl. 3: S47-50
2. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting: current perspectives and future possibilities. Drug Saf 1993; 9 (6): 410-28
3. Aapro MS. Controlling emesis related to cancer therapy. Eur J Cancer 1991; 27 (3): 356-61
4. Fozard JR. MDL 72222: a potent and highly selective antagonist of neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 36
5. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-9
6. 3 receptors mediate cytotoxic drug and radiation-evoked emesis. Eur J Cancer 1987; 56: 159-62
7. Miner WD, Sanger GJ, Turner DH. Comparison of the effect of BRL 24924, metoclopramide and domperidone on cis-platin-induced emesis in the ferret. Br J Pharmacol Proc 1986; Suppl. 88: 374P
8. 3 receptor antagonists: An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42 (4): 551-68
9. 3 receptor antagonists. Hosp Formul 1994; 29 Suppl. 5: S4-9
10. 3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1991; 344: 143-49
11. 4 receptors of the release of 5-hydroxytryptamine from the guinea pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 137-40
12. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13 (4): 1036-43
13. Kytril (granisetron hydrochloride injection) prescribing information. Philadelphia: SmithKline Beecham Pharmaceuticals, Aug. 1995
14. Zotran (ondansetron hydrochloride injection) prescribing information. Cerenex Pharmaceuticals, Division of Glaxo Wellcome, Aug, 1993
15. Lee CR, Plosker GL, McTavish D. Tropisetron: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925-43
16. 3 receptors. Drug Dev Res 1993; 28: 87-93
17. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer 1996; 32A (5): 807-13
18. Galvan M, Claverie N, Hahne W. Pharmacology and metabolism of dolasetron mesilate. European Hospital Pharmacy 1996; 2 Suppl. 1: S12-4
19. 3 receptor antagonists the same? Eur J Cancer 1992; 28A Suppl. 1: S2-6
20. Van Wijngaarden I, Tulp MThM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharm Mol Pharmacol 1990; 188: 301-12
21. 3 receptors. Neuropharmacology 1993; 32: 729-35
22. Chevallier B, Bleiberg H, Fauser AA, et al. Dolasetron in the control of chemotherapy-induced nausea and vomiting. European Hospital Pharmacy 1996; 2 Suppl. 1: S38-42
23. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996; 32A (5): 1523-9
24. 3) receptor antagonist (MDL 73, 147EF) in patients receiving high dose cisplatin chemotherapy [abstract]. Proc Am Soc Clin Oncol 1992; 11: 395
25. Yeilding AL, Bertoli L, Eisenberg PD, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high dose cisplatin-containing chemotherapy. Am J Clin Oncol 1996; 19: 619-23
26. Hesketh P, Navari R, Grate T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242-9
27. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996; 4: 141-6
28. Kris MG. Phase II trials of ondansetron with high-dose cisplatin. Semin Oncol 1992; 19 (4) Suppl. 10: 23-7
29. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994; 51: 762-71
30. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol 1994; 21 Suppl. 5: 15-21
31. Bonneterre J, Hecquet B. Granisetron IV compared with ondansetron IV plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized cross-over study. Seventh European Conference of Clinical Oncology meeting: 1993 Nov: Jerusalem, Israel: 22-4
32. 5 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer 1993; 29A: 1669-72
33. Perez EA, Lembersky B, Kaywin P, et al. Intravenous granisetron vs. ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double blind crossover study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 543
34. Perez EA, Chawla SP, Kaywin P, et al. Efficacy and safety of oral granisetron vs. IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting [abstract]. Proc Am Soc Clin Oncol 1997; 16: 43a
35. Noble A, Bremer K, Dilly SG. A double-blind, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference, Eur J Cancer 1994; 30A: 1083-8
36. Ruff P, Paska W, Groedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin induced acute emesis: a multicentre double-blind, randomized, parallel-group study. Oncology 1994; 51: 113-8
37. 3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 428
38. Martoni A, Angeleli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cis-platinum induced emesis: an open randomized cross-over study [abstract]. Proc Soc Am Clin Oncol 1994; 13: 431
39. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-8
40. Gralla RJ, Popovic W, Strupp J, et al. Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomised study of oral granisetron vs. IV ondansetron [abstract]. Proc Am Soc Clin Oncol 1997; 16: 52a
41. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 1991; 24: 277-84
42. Lifsey DS, Gralla RJ, Clark RA, et al. Electrocardiographic changes with serotonin antagonist antiemetic: rate of occurrence and clinical relevance [abstract]. Proc Am Soc Clin Oncol 1993; 12: 463
43. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278-82
44. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain [letter]. Lancet 1992; 340: 1107
45. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204-10
46. Riviere A, Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69 (5): 967-71
47. Soukop M, Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Supp Care Cancer 1994; 2: 177-83
48. Beck TM, Hesketh PJ, Madajewicv S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969-75
49. Seynaeve C, Schuller J, Buser K, et al. Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomized, parallel group study. Br J Cancer 1992; 66(1): 192-7
50. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10